Login to Your Account



Other News To Note


Wednesday, September 18, 2013
• Compugen Ltd., of Tel Aviv, Israel, said an immune system checkpoint protein, CGEN-15049, showed an ability to regulate an array of different immune cells, making it a potential target for monoclonal antibody immunotherapy in the area of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription